Telomerase activity, which has fundamental roles in development and carcinogenesis, strongly depends on the expression of human telomerase reverse transcriptase (hTERT), its catalytic subunit. In this report, we show that the basic helix-loophelix factor, TAL1 (T-cell acute lymphoblastic leukemia 1), is a negative regulator of the hTERT promoter. Indeed, TAL1 overexpression leads to a decrease in hTERT mRNA abundance and hence to reduced telomerase activity. Conversely, suppression of TAL1 by RNA interference in Jurkat cells increases hTERT expression. Analysis by chromatin immunoprecipitation assays showed that TAL1 binds to the hTERT proximal promoter and recruits HDAC1. Considering the relationship recently established between TAL1 and the human T-cell leukemia virus type 1 (HTLV-1) Tax protein, which was confirmed in T lymphocyte clones derived from adult T-cell leukemia patients, we analyzed the effect of TAL1 with respect to the earlier characterized effects of Tax and HBZ (HTLV-1 basic leucine zipper) on hTERT expression. TAL1 was observed to reinforce the negative effect of Tax, whereas hTERT transactivation by the HBZ-JunD complex was repressed by TAL1 overexpression. Moreover, HBZ was found to induce proteasome-mediated degradation of TAL1. These observations support a model in which Tax and TAL1 by repressing hTERT would initially favor genomic instability, whereas expression of factors such as HBZ allows at a later stage an increase in hTERT production and consequently in telomerase activity.
Introduction
Telomerase enzyme, which has the unique property of increasing the length of the telomeres, has a key function in cancer cells. 1, 2 It has been shown that telomerase is active in many leukemic cells. 3, 4 Telomerase consists of an RNA molecule, hTR, and of a catalytic protein subunit, human telomerase reverse transcriptase (hTERT). 5 The high telomerase activity in leukemic cells is often linked to an elevated expression of hTERT, 6 and in various types of leukemia a decrease in hTERT expression has been linked to reduced proliferation and to higher sensitivity to drug treatment. 7 The hTERT subunit expression is regulated by many transcription factors (for a review, see Kyo et al. 8 ). Its proximal transcription promoter sequences include two E-boxes and five Sp1-binding sites. These E-boxes have been shown to be regulated positively by the MycMax complex and negatively by Mad-Max. [9] [10] [11] [12] An interesting model of hTERT regulation focused on the opposite effects exerted by the Tax and HBZ (HTLV-1 basic leucine zipper) proteins expressed by the human T-cell leukemia virus type 1 (HTLV-1), the etiological agent of adult T-cell leukemia (ATL). Indeed, it has been shown that the Tax transactivator decreases the activity of the hTERT promoter through the first E-box. 13 Conversely, the HBZ protein, a factor expressed by the antisense strand of the provirus, activates in cooperation with JunD, the hTERT promoter activity. 14 This led to a model suggesting that early after infection Tax decreases telomerase activity, thereby favoring genomic instability. At a later stage, Tax expression is repressed and the expression of HBZ reactivates telomerase expression allowing evolution toward fully transformed leukemic cells. 14 Recently, we have shown that TAL1 (T-cell acute lymphoblastic leukemia 1), which is known to have a key function in T-cell acute lymphoblastic leukemia (T-ALL) by impairing differentiation, 15 is a target of Tax. 16 Indeed, through activation of its transcription promoter 1b, Tax increases TAL1 expression. By considering these data, we asked whether TAL1 is involved in hTERT regulation both in T-ALL and ATL cells. This factor is known to activate or repress many cellular genes. 17 This class II basic helix-loop-helix factor, which has a key function in the differentiation of both hematopoietic and endothelial cells, has been shown to associate with E-boxes as a heterodimer with E protein as E47. 18 TAL1 has also been shown to associate with many different transcriptional regulators, including the LIM-only proteins LMO1 and LMO2, GATA factors, Sp1, mSIN3A and p300. [19] [20] [21] [22] [23] Depending on the combination of factors in which TAL1 is engaged, its effect on a target transcriptional promoter is either positive or negative.
We show in this report that TAL1, similar to Tax, is a repressor of hTERT promoter activity. This effect relies on the Sp1 sites present in the hTERT promoter. Interestingly, Tax and TAL1 can cooperate for hTERT repression, but their effect is counteracted by JunD and HBZ. Our results suggest that TAL1 by inhibiting hTERT might favor genome instability both in T-ALL and ATL cells.
Materials and methods

Constructs
pSGF-TAL1, pSUPER-TAL1 and pSG5-Tax have been described earlier.
16 pSG5-MYC-TAL1 was generated by amplifying it with the appropriate primers, the TAL1-coding sequences from a plasmid including the complete human TAL1 open-reading frame, provided by D Mathieu. The PCR product was inserted between the BglII and XhoI restriction sites in the pSG5-MYC vector. pCDNA3-HBZ-myc and pCMV-JunD-Flag have been described earlier.
14 pCMV-Sp1 was kindly provided by Katie Flaig.
24 pGL3-hTERTÀ3300, pGL3-hTert-378 and pGL3-hTert-181 wild-type (WT), mt1, mt2, mt and mutSp1 were kindly provided by Satoru Kyo.
10 pCMV-p300 was kindly provided by Louis Gazzolo. 25 Cell culture, transfection and T-cell limiting dilution cloning Jurkat cells were cultured in RPMI 1640 medium with 10% fetal calf serum (FCS) (Sigma-Aldrich, St Louis, MO, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco Invitrogen, San Diego, CA, USA) at 37 1C in a 5% CO 2 -humidified atmosphere. HeLa cells were cultured in Dulbecco's modified Eagle's medium with 10% FCS (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin at 37 1C in a 5% CO 2 -humidified atmosphere. For transfection, FCS concentration was reduced to 5%. Jurkat cells were transfected using the Nucleofector kit (Amaxa, Cologne, Nordrhein-Westfalen, Germany). HeLa cells were stably transfected with the pCEP-FLAG-TAL or the control pCEP-FLAG-GFP constructs, as described earlier. 16 Expression vectors were transfected using the calcium phosphate precipitation method as described earlier. 16 To achieve inhibition of the proteasome, we added MG132 (Sigma-Aldrich) at 10 mM for 6 h. Cellular extracts were normalized with respect to protein concentrations that were quantified with the DC protein assay kit (Bio-Rad, Hercules, CA, USA). For immunoprecipitations, cellular extracts adjusted to equal protein concentrations were incubated for 2 h with antibodies diluted 1:250. Protein A beads (40 ml) were then added to the mixes that were then incubated for 1 h. Beads were collected by centrifugation and washed three times in lysis buffer. Proteins were eluted in 2 Â SDS sample buffer at 80 1C for 10 min. Peripheral blood mononuclear cells (PBMCs) were cloned in limiting dilution (0.1 cell per well) in Terasaki plates after removal of adherent cells. The medium used for T lymphocytes was RPMI 1640 containing penicillin and streptomycin, sodium pyruvate, nonessential amino-acid solution, 2-mercapto ethanol, 10% filtered human AB serum and 100 U/ml recombinant IL-2 (Chiron Corporation, Emeryville, CA, USA). The cloning medium was the medium used for T lymphocytes supplemented with 1 mg/ml PHA (Abbott Murex HA 16, Abbott, Abbott Park, IL, USA) and 5 Â 10 5 per ml irradiated (30 Gy) allogeneic PBMCs (feeder cells). The Terasaki plates were stored at 37 1C for 10 days in aluminum foil, then screened for growing cells under the microscope. Positive cultures were transferred to 96-well U-bottom plates in medium for T lymphocytes and re-stimulated after a few days. T lymphocytes were re-stimulated every 14 days with PHA (1 mg/ml) and fresh feeder cells (10 6 per ml). Lethally irradiated PBMCs from three distinct allogeneic, HTLV-I-negative donors were used as feeder cells to exclude the possibility of clones becoming infected in vitro. To preserve the original growth characteristics of the cells, we maintained clones in this way for no more than 4 months, after which a fresh aliquot was thawed.
Immunoblot
After separation by SDS-polyacrylamide gel electrophoresis, proteins were transferred to a polyvinylidene difluoride membrane (GE Healthcare). For immunoblot, primary antibodies were diluted 1:1000 or as indicated by the manufacturer, and detection was performed by chemiluminescence using enhanced chemiluminescence (ECL) or ECL þ kits (GE Healthcare).
Antibody against HTLV-1 Tax was obtained from the AIDS Research and Reference Reagent program catalog. The following antibodies were purchased: FLAG (clone M2; SigmaAldrich), b-actin (Sigma-Aldrich) and MYC (clone 9E10; Sigma-Aldrich).
Real-time quantitative telomeric repeat amplification protocol
Stably transfected HeLa cells were trypsinized, washed twice in phosphate-buffered saline and resuspended in 3-((3-cholamidopropyl)-dimethylammonio)-1-propanesulfonate (CHAPS) lysis buffer (10 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , 1 mM EGTA, 0.5% CHAPS (w/v), 10% (w/v) glycerol, 0.1 mM phenylmethylsulfonyl fluoride, 5 mM b-mercaptoethanol) at 10 7 cells per ml. After 30 min lysis at 4 1C, lysates were centrifuged at 14 000 g for 30 min at þ 4 1C and the supernatants were stored at À80 1C.
Samples were diluted at a final concentration of 300 ng/ml. The sample dilution (1 ml) was used to perform the real-time quantitative telomeric repeat amplification protocol (RQ-TRAP) assay with 5 ng/ml of TS primer (5 0 -AATCCGTCGAGCAGAGT T-3 0 ), 2.5 ng/ml of ACX primer (5 0 -GCGCGGCTTACCCT TACCCTTACCCTAACC-3 0 ), 0. 
Real-time quantitative RT-PCR
Total RNAs were extracted from frozen cells using the RNeasy mini kit (Qiagen, Hilden, Nordrhein-Westfalen, Germany). One-step reverse transcription (RT)-PCR reactions were performed using the QuantiTect SYBR Green RT-PCR kit (Qiagen) and the LightCycler apparatus (Roche). Sequences of sense and antisense primers were as followsF TAL1:
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Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed essentially by using the Upstate Biotechnology Inc. (Charlottesville, VA, USA) recommendations with minor modifications. Formaldehyde cross-linked chromatin from 5 Â 10 6 cells per antibody was used for each immunoprecipitation. Cross-linking reactions were quenched with 125 mM glycine, cells were lysed and chromatin was sonicated to obtain an average DNA length of 500 bp. After centrifugation, the chromatin was diluted 10-fold and pre-cleared with protein A-agarose containing salmon sperm DNA and bovine serum albumin (Upstate Biotechnology). Pre-cleared chromatin (2 ml) was incubated overnight at þ 4 1C with 10 mg of antibody to Sp1, to HDAC1 or to p300 (sc-14027, sc-6928 or sc-585, respectively; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or anti-FLAG antibody followed by protein A-agarose immunoprecipitation. Eluted protein-DNA cross-links were reversed by heating at 65 1C overnight, and 25% of the recovered DNA was used in the PCR reaction to amplify the 278 bp region of the hTERT proximal promoter with the Phusion high-fidelity DNA polymerase enzyme (Ozyme, Saint Quentin Yvelines, Yvelines, France) along with the forward primer (À190/À171) 5 0 -CACAGACGCC CAGGACCGCG-3 0 and the reverse primer (
A control PCR (negative control leading to a 150 bp fragment) was also performed from a region devoid of Sp1 sites within the distal region of hTERT using forward primer (À2916/À2897) 5 0 -GGCAGGCACGAGT GATTTTA-3 0 and reverse primer (À2782/À2763) 5 0 -CTGAGG CACGAGAATTGCTT-3 0 to show the specificity of Sp1 sites located on the proximal hTERT in the ChIP assay. DNA samples recovered from chromatin samples before immunoprecipitation, which corresponds to 1% of chromatin samples included in each immunoprecipitation reaction, were also PCR-amplified as loading controls. The PCR reactions for hTERT were processed through 32 cycles of 98 1C for 10 s and 71 1C for 30 s, followed by one cycle for 7 min at 72 1C. PCR products were separated on 2% agarose gel and visualized with ethidium bromide staining.
Results
Inhibition of hTERT expression by TAL1
To examine the effect of TAL1 on hTERT expression, we transfected HeLa cells either with a control or with a TAL1 expression vector, and mRNA produced by the endogenous htert gene was quantified by quantitative RT-PCR (qRT-PCR). In these cells, which lack endogenous TAL1, expression of this protein leads to a 40% drop in the amount of hTERT mRNA (Figure 1a) . A similar effect was observed in HeLa cells stably expressing TAL1 from an Epstein-Barr virus (EBV)-derived episomic vector (Figure 1b) . In this experiment, cells transformed by a similar vector expressing green fluorescent protein (GFP) were taken as control. Considering this negative effect of TAL1 on hTERT expression, we further examined how it affected the telomerase activity. This was measured by an RQ-TRAP assay using HeLa cells transformed by the GFP and TAL1 episomic vectors. In agreement with the earlier data, an approximate 30% drop in telomerase activity was observed when TAL1 was expressed (Figure 1c) . The effect of TAL1 on hTERT expression was also examined in lymphoid cells. In the leukemic T-cell line Jurkat, overexpression of TAL1 markedly reduced in a dose-dependent manner the activity of a reporter construct driving luciferase production under the control of the hTERT promoter (Figure 2a) . Conversely, expression in these cells of an shRNA that was effective in reducing TAL1 expression (Figure 2c ) led to an increase in the activity of the reporter construct (Figure 2b ). This effect showed that the endogenous level of TAL1 present in these cells exerts a negative The telomerase activity is expressed as a ratio FLAG-TAL/FLAG-GFP. One and two stars indicate a Student's t-test P-value less than 0.05 and 0.01, respectively.
hTERT inhibition by TAL1 J-M Terme et al effect on transcription driven by the hTERT promoter. Collectively, these data suggest that TAL1 is a negative regulator of hTERT transcription in T-ALL cells.
Interference of TAL1 with stimulation of the hTERT promoter activity by Sp1
To better understand this negative effect of TAL1 on the hTERT promoter activity, we set out to characterize the promoter hTERT inhibition by TAL1 J-M Terme et al sequence mediating the activity of TAL1. As a first step, reporter constructs with various portions of the 5 0 upstream promoter sequences were tested. The negative effect of TAL1 was observed similarly with the three constructs starting at positions À3300, À378 and À181 with respect to the transcription start site (Supplementary Figure 1) . This effect of TAL1 was dose dependent (Supplementary Figure 2) . This indicated that the TAL1 effect is exerted on the proximal part of the promoter that includes two E-boxes and a series of five Sp1-binding sites (Figure 3a) . When E-boxes were mutated either individually hTERT inhibition by TAL1 J-M Terme et al or both together, the effect of TAL1 was still apparent (Figures 3b-e) . The negative effect of TAL1 was similar and even slightly stronger on the reporter construct bearing mutations of both E-boxes than on the WT construct (Figure 3 , compare b and e). By contrast, mutation of the five Sp1-binding sites led to a reduction in the intensity of the TAL1 effect on the promoter (Figure 3 , compare b and f). This result indicated that TAL1 might reduce the hTERT promoter activity through an effect on Sp1. To further test this point, we examined the effect of TAL1 overexpression on stimulation of the hTERT promoter activity by Sp1. Transfection of cells with an Sp1 expression vector increased the activity of the hTERT promoter (Figure 4a , compare lanes 1 and 2), but co-expression of increasing amounts of TAL1 was able to block this activity (Figure 4a , compare lanes 1, 2 and 5). A similar effect was observed with the p300 cofactor (Figure 4b ). These results show that TAL1 expression interferes with the activation of the hTERT promoter by the DNA-binding Sp1 transcription factor and the p300 cofactor, both well-established positive regulators of hTERT. To further understand how TAL1 modifies Sp1 and p300 association with the hTERT promoter, we performed ChIP experiments using cells transformed with episomic vectors expressing either FLAG-GFP or FLAG-TAL1. These assays were performed with two primer couples amplifying either the distal or the proximal hTERT promoter. Interestingly, this approach revealed that FLAG-TAL1 associates with the proximal hTERT promoter (Figure 4c , upper panel, compare lanes 3 and 4). This was also observed by performing a DNA precipitation assay using extracts of these cells (Supplementary Figure 3) . The ChIP assays also showed that TAL1 increased Sp1 binding to the proximal promoter, while slightly reducing p300 association (Figure 4c , upper panel, compare lanes 7 and 8 and lanes 9 and 10, respectively). As the binding of both Sp1 and p300 to the proximal hTERT promoter did not provide a clear explanation of the effect of TAL1, we also tested the histone deacetylase (HDAC1), which has been shown earlier to form a complex with TAL1 and mSIN3A. 19 In the absence of TAL1, HDAC1 did not associate with the hTERT proximal promoter, whereas in the presence of TAL1 a clear signal was detected (Figure 4c , upper panel, compare lanes 5 and 6). None of these factors were observed to bind to the distal hTERT promoter. Collectively, these results indicate that the repression of the hTERT proximal promoter correlates with TAL1 and HDAC1 binding.
Cooperation between Tax and TAL1 to repress hTERT and impairment of this negative effect by HBZ
Earlier studies have shown that hTERT expression was modulated by proteins expressed by the HTLV-1 provirus. 13, 14 It has been established that the Tax transactivator has a negative effect on hTERT expression, whereas the HBZ protein expressed from the reverse strand of the provirus 26 was able to stimulate this expression in combination with JunD. We also observed earlier a cross talk between Tax and TAL1, which mutually reinforced their expression through stimulation of their respective promoters. 16 After considering this, it appeared interesting to examine the effect of TAL1 on hTERT with respect to these viral proteins. As observed earlier, Tax was able to reduce hTERT expression, in the same way as the effect exerted by TAL1 (Figure 5a,  compare lanes 2 and 3) . Co-expression of both proteins led to a reinforced negative effect (Figure 5a, compare lanes 2 and 4) . This effect was not related to an increase in the amount of Tax protein in the presence of TAL1 (Figure 5b, compare lanes 3 and  4) , showing that both factors can cause a marked reduction in hTERT production. We also tested whether this effect could be observed in HTLV-1-infected cells. A first analysis was performed in CD4 þ clones expressing Tax derived from infected patients. 27 In these cells, a positive correlation was hTERT inhibition by TAL1 J-M Terme et al observed between Tax and TAL1 expression (Table 1) . This is in accordance with our previous work that showed a mutual positive effect between Tax and TAL1 expression. 16 In this analysis, a negative correlation was observed between either TAL1 and hTERT or Tax and hTERT, although with limited significance levels probably as a consequence of the limited number of clones available for analysis (Table 1) . A negative correlation between TAL1 and hTERT expression was also observed in ATL cells and in uninfected T lymphocytes reflecting the negative function of TAL1 on hTERT expression (Table 1) .
In agreement with earlier observations, by contrast with Tax or TAL1, co-expression of HBZ and JunD had a clear stimulatory effect on the activity of the reporter construct including the hTERT promoter (Figure 6a, compare lanes 1 and 2) , but production of increasing amounts of TAL1 antagonized this effect (Figure 6a) . Conversely, co-expression of the shRNA targeting TAL1 was able to reinforce the stimulatory activity of HBZ/JunD (Figure 6b ). This shows that the endogenous TAL1 present in leukemic Jurkat cells had a negative effect on HBZ/ JunD transactivation. In accordance with these observations, it was also observed that HBZ/JunD was able to impair the negative effect of TAL1 on endogenous hTERT mRNA expression (Figure 6c ).
To further understand how HBZ interferes with TAL1, the effect of the viral protein on the amount of TAL1 was analyzed by immunoblot. Unexpectedly, expression of increasing amounts of HBZ was found to cause a profound reduction in the TAL1 concentration (Figure 7a, upper panel) . As the proteasome inhibitor, MG132, was able to block this effect (Figure 7b , compare lanes 2 and 3, upper panel), it appeared that HBZ stimulates TAL1 degradation by the proteasome. This effect is likely related to an interaction between both proteins. Indeed, in the presence of MG132, TAL1 and HBZ were found to coprecipitate (Figure 7c , lane 5). Despite this interaction between TAL1 and HBZ, TAL1 expression did not weaken the association of HBZ with JunD (Supplementary Figure 4) . Collectively, these data show that HBZ by interacting with TAL1 triggers its degradation, thereby impairing its negative effect on the activity of the hTERT promoter. Tax and HBZ therefore appeared to have opposite effects on TAL1 and hTERT expression.
Discussion
TAL1 has an important function in T-ALL by being inappropriately expressed in the T-cell lineage as a consequence of translocation or deletion placing the gene under the control of the SIL promoter. 28, 29 It is also estimated that TAL1 is often abnormally expressed in T-ALL as a consequence of epigenetic activation. 30 As telomerase is often highly active in transformed cells, a negative effect of TAL1 on the hTERT expression was unexpected. Telomerase activity is determined by the expression level of both its hTERT and hTR components, which are limiting. 31 In agreement with this notion, we observed that overexpressing TAL1 in cells leads to a decrease in the telomerase activity. We also observed that suppression of TAL1 by RNA interference in Jurkat cells raised the amount of hTERT indicating that the negative effect of TAL1 intervenes at physiological concentrations. In agreement with these experiments performed in cell lines, we also observed a negative correlation between TAL1 and hTERT expression in T lymphocytes expressing either Tax or not, as well as in ATL cells. However, these correlations were obtained with uncertain significance levels and have to be confirmed with a larger set of patients. Despite this limitation, these data obtained in various cells by different experimental approaches collectively support the notion that TAL1 is a negative regulator of telomerase. This effect of TAL1 on hTERT depends on the proximal promoter. As E-boxes are present in this part of the promoter, there is a possibility of interference of TAL1 with these motifs, which have been shown to be regulated by the Myc-Max complex. However analysis of mutated constructs clearly showed that the effect of TAL1 did not depend on these sequence motifs, but on the Sp1-binding sites. In agreement with this observation, overexpression of TAL1 was able to impair stimulation of hTERT promoter activity by Sp1, as well as by p300. A negative effect of TAL1 on different promoters is well established, 17 and it has been shown to allow recruitment of transcriptional repressors such as mSIN3A and HDAC1. 19 The ChIP assays performed in this study clearly show that TAL1 associates with the hTERT promoter, likely through an interaction with Sp1. A direct explanation to the consequent transcriptional repression was provided by the TAL1-induced recruitment of HDAC1 on the promoter. Indeed, the presence of p300 was weakly affected. These observations show that, similar to other promoters, the repressive effect of TAL1 is because of the induced association of a histone deacetylase to the promoter.
A consequence of the negative effect of TAL1 on hTERT expression is to favor genome instability, which has been observed in many types of leukemia as well as telomere shortening. 7, 32 This effect probably drives a mutagenic effect in favor of the development of a fully transformed phenotype. At late stages of transformation, it cannot be excluded that this negative effect of TAL1 is countered by other events stimulating hTERT expression. Our observations of the Tax and HBZ protein effects on the TAL1 inhibition of hTERT are in favor of such a model. Indeed, it has been reported earlier that Tax inhibits hTERT transcription and that HBZ in combination with JunD activates it. 13, 14 It is thought that Tax is highly expressed at early stages of infection before an active immune response blocks expression of the protein. During later stages of infection, several arguments support a very low expression of Tax in ATL cells because of deletion or hypermethylation of the 5 0 LTR and even in some cases to the appearance of stop codons in the Tax coding sequence. [33] [34] [35] By contrast, the HBZ RNA is well expressed in ATL cells. 36, 37 From these observations, it has been proposed that Tax by inhibiting hTERT favors an unstable genomic state at early steps of transformation, whereas at late stages HBZ would drive with JunD a high expression of hTERT and consequently a high telomerase activity. 14 We show here that TAL1 can reinforce hTERT repression. As we have shown earlier that there was a positive cross talk between the expression of both factors, 16 our data support the notion that TAL1 participates in the negative effect of Tax on hTERT. 13 However, HBZ can block this inhibition. As the activity of the JunD-HBZ complex depends on the Sp1-binding sites of the hTERT promoter, it is possible that some competition exists between JunD-HBZ and TAL1, the former impeding the association of the latter with the promoter. Alternatively, JunD-HBZ by allowing an active recruitment of p300 could block the negative effect of TAL1. However, we also observed that HBZ degrades TAL1. Such an effect of HBZ has already been observed with c-Jun. 38 So HBZ clearly blocks the negative effect of TAL1 on hTERT and this is likely to participate in the reactivation of the telomerase activity in fully transformed cells. Such an effect might be mediated by other factors in non-viral T-ALL because of mutation events. In particular, it is possible that activation of the Notch-Myc pathway in leukemic cells reverts the negative effect of TAL1 on hTERT. Indeed, it has been shown earlier that Notch was able to induce polyubiquitination and proteasome-mediated degradation of TAL1 39 and that Myc can transactivate hTERT. [39] [40] [41] In conclusion, our data established TAL1 as an important regulator of hTERT. Our results add to the complexity of the regulation of this key protein, which has an essential function in cellular transformation. This strengthens the interest of potential manipulation of the activity of telomerase in a therapeutic goal. Alternatively, it could be important to inhibit TAL1 at early stages to avoid genome instability, thus paving the way for full cellular transformation.
